Understanding Major Adverse Cardiovascular Events
MACE encompasses the most serious outcomes following acute coronary syndrome: death from any cause, acute myocardial infarction (heart attack), and interventional procedures including percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). These endpoints are tracked over a six-week window following presentation.
Multiple conditions elevate MACE risk: established coronary artery disease, age over 65, significant coronary stenosis, dyslipidemia (elevated blood lipids), and diabetes mellitus. Other contributors include hypertension, tobacco use, obesity, and positive family history of premature coronary disease. Understanding individual risk profiles helps clinicians make informed decisions about admission versus outpatient management.
HEART Score Calculation
The HEART score integrates five clinical variables, each contributing 0–2 points. The total ranges from 0–10, with higher scores indicating greater risk of MACE within six weeks.
HEART Score = Age + ECG + Risk Factors + Initial Troponin + ACS History
Age— ≤45 years (0 points); 46–64 years (1 point); ≥65 years (2 points)ECG— Normal (0 points); abnormal without ST deviation (1 point); significant ST deviation present (2 points)Risk Factors— Number of major risk factors present: hypercholesterolaemia, hypertension, diabetes, smoking, obesity, or positive family history. 0 factors (0 points); 1–2 factors (1 point); 3+ factors (2 points)Initial Troponin— Normal for lab (0 points); 1–3 times upper limit of normal (1 point); >3 times upper limit of normal (2 points)ACS History— Nonspecific symptoms (0 points); indeterminate history (1 point); typical acute coronary syndrome features (2 points)
Clinical Application and Risk Stratification
The HEART score identifies low-risk patients (0–3 points) with <2% risk of MACE, who can be safely discharged for outpatient follow-up without hospital admission. This decision support tool is designed for undifferentiated chest pain presentations without established acute coronary syndrome diagnosis.
Intermediate-risk patients (4–6 points) warrant additional testing including serial troponins and stress evaluation. High-risk patients (7–10 points) require hospital admission, intensive monitoring, and aggressive intervention. The score should never replace clinical judgment; patients with atypical presentations, comorbidities, or concerning symptoms may need admission regardless of score.
Critical Considerations When Using the HEART Score
Accurate scoring depends on precise clinical assessment and appropriate test interpretation.
- ECG interpretation is foundational — New or unknown ST-segment changes dramatically shift risk stratification. Always compare with prior ECGs when available. Confounding patterns like left ventricular hypertrophy, bundle branch block, or digoxin effect can obscure acute ischaemic changes.
- Troponin timing matters significantly — Serial troponin measurements improve diagnostic accuracy. A single normal troponin at presentation does not exclude MI, particularly in early presentations. Most laboratories define upper normal limits; exceed this threshold considerably before assigning higher points.
- Don't neglect atypical presentations — Elderly patients, women, and those with diabetes frequently present with atypical or minimal symptoms. A low HEART score should not override clinical suspicion when presentation is unusual or the history is vague.
- Use as one tool within a comprehensive assessment — The HEART score guides decision-making but does not replace clinical reasoning. Patient factors like access to follow-up care, reliability for outpatient monitoring, and social circumstances influence safe discharge decisions.
Evidence and Validation
The HEART score evolved from extensive research in emergency medicine, demonstrating strong predictive value for identifying genuinely low-risk presentations suitable for early discharge. Studies consistently show that patients in the low-risk category have event rates below 2% at six weeks, reducing unnecessary hospital admissions and associated costs.
However, no risk stratification tool achieves perfect sensitivity and specificity. Approximately 1–2% of low-risk patients may experience MACE, emphasizing the need for robust outpatient follow-up, clear discharge instructions, and patient education regarding return precautions. The score performs best when integrated within systems supporting timely troponin measurement, ECG acquisition, and structured follow-up protocols.